Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant human papillomavirus vaccine bivalent (types 16 + 18)
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
**Recombinant human papillomavirus vaccine bivalent (types 16 + 18)** is a prophylactic vaccine targeting human papillomavirus types 16 and 18, the two main oncogenic HPV serotypes responsible for approximately 70% of cervical cancer cases worldwide[4][2]. This vaccine uses recombinant technology to generate virus-like particles (VLPs) of the L1 protein from types 16 and 18, which induce a specific immune response, leading to production of neutralizing antibodies that prevent persistent infection and associated cervical intraepithelial neoplasia and cancer. Clinical studies have shown that this bivalent vaccine provides robust, durable protection—up to 11 years—against high-grade cervical lesions (CIN2+ and CIN3) caused by HPV-16/18 in HPV-naive populations[2][4].
- Brand names
- Cervarix
- Other names
- bivalent HPV vaccineHPV-16/18 vaccineHPV bivalent vaccine
02
Targets
HPV16 (Human papillomavirus type 16)HPV18 L1TLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on recombinant human papillomavirus vaccine bivalent (types 16 + 18).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant human papillomavirus vaccine bivalent (types 16 + 18).